Marker Therapeutics Inc
MRKR
NASDAQ
Biotechnology
$1.14
USD
+0.03 (+2.70%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $18.67M
Volume 45.6K
Revenue
$3.20M
TTM
-40.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-10.90M
TTM
+14.8%
YoY
Operating Cash Flow
$-7.92M
TTM
+37.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.9 | 1.2 | 1.1 | 0.0 |
YoY Growth | -100.0% | -26.3% | -36.0% | -51.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.9 | 1.2 | 1.1 | 0.0 |
Selling, General & Administrative | 1.4 | 0.9 | 1.0 | 0.8 | 1.2 |
Other Operating Expenses | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 5.0 | 5.1 | 3.4 | 3.0 | 4.1 |
Operating Income | -5.0 | -4.3 | -2.1 | -1.9 | -4.1 |
EBITDA | -4.5 | -4.3 | -2.1 | -1.9 | -4.1 |
Other Income / Expense | 0.3 | 0.1 | 0.0 | 0.0 | 0.8 |
Total Other Income / Expense | 0.5 | 0.2 | 0.1 | 0.2 | 0.9 |
Income Before Income Taxes | -4.4 | -4.0 | -2.0 | -1.7 | -3.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | -0.0 | 0.0 |
Net Income | -4.4 | -4.0 | -2.0 | -1.7 | -3.2 |
Consolidated Net Income / Loss | -4.4 | -4.0 | -2.0 | -1.7 | -3.2 |
Net Income Attributable to Common Shareholders | -4.4 | -4.0 | -2.0 | -1.7 | -3.2 |
Basic EPS | -$0.40 | -$0.29 | -$0.12 | -$0.09 | -$0.16 |
Diluted EPS | -$0.40 | -$0.29 | -$0.12 | -$0.09 | -$0.16 |
Basic Shares Outstanding | 11.1M | 14.0M | 16.8M | 19.4M | 19.3M |
Diluted Shares Outstanding | 11.1M | 14.0M | 16.8M | 19.4M | 19.3M |